Format

Send to

Choose Destination
Cephalalgia. 2018 Sep;38(10):1611-1621. doi: 10.1177/0333102418788347. Epub 2018 Jul 8.

Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study.

Author information

1
1 Danish Headache Center and Department of Neurology, Rigshospitalet Glostrup, Faculty of Medical and Health Sciences, University of Copenhagen, Copenhagen, Denmark.
2
2 Geisel School of Medicine at Dartmouth, Hanover, NH, USA.
3
3 Nashville Neuroscience Group and Department of Neurology, Vanderbilt University, Nashville, TN, USA.
4
4 Department of Neurology, Charité Universitätsmedizin Berlin, Berlin, Germany.
5
5 Headache Unit, Neurology Department, University Hospital Center of Montreal, Montreal, QC, Canada.
6
6 Prague Headache Center, DADO MEDICAL s.r.o., Prague, Czech Republic.
7
7 Amgen Inc., Thousand Oaks, CA, USA.
8
8 Novartis Pharma AG, Basel, Switzerland.

Abstract

Background Erenumab was effective and well tolerated in a pivotal clinical trial of chronic migraine. Here, we evaluated efficacy and safety of monthly erenumab (70 mg or 140 mg) versus placebo in the subgroup of patients who had previously failed preventive treatment(s) (≥ 1, ≥ 2 prior failed medication categories) and in patients who had never failed. Methods Subgroup analyses evaluated change from baseline in monthly migraine days; achievement of ≥ 50% and ≥ 75% reduction in monthly migraine days; and change in monthly acute migraine-specific medication days. Adverse events were evaluated for each subgroup. Results Treatment with both doses of erenumab resulted in greater reductions in monthly migraine days (primary endpoint) at Month 3 (treatment difference [95% CI], never failed subgroup: -2.2 [-4.1, -0.3] for 70 mg and -0.5 [-2.4, 1.5] for 140 mg; ≥ 1 prior failed medication categories subgroup: -2.5 [-3.8, -1.2], for 70 mg and -3.3 [-4.6, -2.1] for 140 mg; ≥ 2 prior failed medication categories subgroup: -2.7 [-4.2, -1.2], for 70 mg and -4.3 [-5.8, -2.8] for 140 mg). Similar results were observed in the monthly acute migraine-specific medication days endpoint, and in the achievement of ≥ 50% and ≥ 75% reduction in monthly migraine days. There were no new or unexpected safety issues. Conclusion Erenumab showed consistent efficacy in chronic migraine patients who had failed prior preventive treatments and was well tolerated across subgroups.

KEYWORDS:

Erenumab; chronic migraine; clinical trial of prophylactic migraine treatment; prior preventive treatment failure; prior prophylactic treatment failure

PMID:
29984601
DOI:
10.1177/0333102418788347
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center